Genmab A/S (NASDAQ:GMAB) Shares Sold by Capital International Investors

Capital International Investors lessened its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 41.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,570,909 shares of the company's stock after selling 1,850,708 shares during the quarter. Capital International Investors owned 0.39% of Genmab A/S worth $53,398,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GMAB. Marshall Wace LLP grew its holdings in Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after purchasing an additional 694,243 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Genmab A/S by 12.7% during the 4th quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock valued at $403,000 after acquiring an additional 2,171 shares in the last quarter. Barclays PLC raised its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $2,463,000. Finally, Renaissance Technologies LLC grew its position in shares of Genmab A/S by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after purchasing an additional 139,722 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Trading Up 0.2 %

NASDAQ:GMAB traded up $0.05 during trading hours on Friday, hitting $20.59. The stock had a trading volume of 715,774 shares, compared to its average volume of 1,049,159. The company has a market cap of $13.63 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. The business has a 50 day simple moving average of $20.47 and a two-hundred day simple moving average of $21.06. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GMAB. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.